Fig. 4.
Stimulus-locked waveforms (current source density) and topographic maps (for Nogo trials only) for activation in the RIDE C-Cluster. Figure shows A) the P3RIDE at electrode Cz and B) the P3 RIDE at electrode Pz for Go and Nogo trials, for both time points (T1 = baseline testing, T2 = testing after 8 weeks of intervention/waiting list status) and for all three experimental groups (MPH = patients treated with methylphenidate; NF = patients treated with neurofeedback; WLC = patients included as waiting list controls). Point 0 denotes Go/Nogo stimulus onset. In the topographic maps (shown only for Nogo trials), blue denotes negative deflections whereas red denotes positive ones. sLORETA images show contrasts in Nogo trials between the two time points for the two intervention groups and reveal activation differences in the medial frontal cortex and the anterior cingulate cortex (ACC) (BA24, BA32) for the patients treated with MPH. For the patients treated with NF, sLORETA showed activation differences in the medial frontal cortex, but also in the inferior parietal cortex (BA40) encompassing the temporo-parietal junction (TPJ). Colours indicate the critical t-value (corrected for multiple comparison using SnPM).